☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
Episodic
Amgen Reports Results of Aimovig (erenumab-aooe) in P-lV Study for the Treatment of Episodic and Chronic Migraine
November 9, 2021
Eli Lilly Reports Results of Emgality (galcanezumab-gnlm) in P-III CONQUER Study for Chronic and Episodic Migraine
August 5, 2019
Eli Lilly's Emgality (galcanezumab-gnlm) Receives FDA's Approval for Episodic Cluster Headache in Adults
June 5, 2019
Load more...
Back to Home
Modal title
×
Modal body text goes here.